First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors

Overview of attention for article published in Clinical Cancer Research, April 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

So far, Dimensions has found 41 publications that cite this research output.

Preprint in medRxiv (April 2024)

Article in Marine Drugs (February 2024)

Article in Current Treatment Options in Oncology (January 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.